PRESS RELEASE PRESS RELEASE PRESS RELEASE     ZedScan from Zilico wins prestigious Bionow Award ZedScan I, the revolutionary cervical cancer diagnostic device from Zilico Ltd, has won the Award for Best Product or Service at the Bionow Annual Awards 2013. Zilico’s Chief Executive Sameer Kothari collected the award, sponsored by UL EduNeering, at Bionow’s Annual Awards Dinner at the Mere Golf Resort & Spa, Cheshire, with more than 300 executives from across the biomedical sector in attendance. The event, which was hosted by Dr John Stageman OBE, Chair of Bionow and Dr Geoff Davison, CEO of Bionow, showcases the best of business growth, competitiveness and innovation within the biomedical and life science sectors across Northern England. ZedScan I, which recently received EC certification from its notified body, offers more accurate detection of cervical neoplasia in real-time, enabling clinicians to improve patient management. The ZedScan I system is used alongside colposcopy on women identified with an abnormal smear result. ZedScan offers clinical benefits by identifying those patients who require treatment at first visit, facilitating a wider use of “Select & Treat” in addition to reducing the number of cervical biopsies performed on each patient by pin-pointing the optimum site for biopsy. Zilico’s patented Electrical Impedance Spectroscopy (EIS) technology exploits the different electrical resistivity of normal, pre-cancerous and cancerous tissue. Zilico Ltd, based at Manchester Science Park, was also shortlisted in the Healthcare Project of the Year category at the Bionow Awards, as well as being recently highly commended for ZedScan I in the Institute of Engineering and Technology (IET) Innovation Awards. Sameer Kothari, Chief Executive of Zilico Ltd, said: “We are delighted to have won this prestigious Bionow Award for ZedScan I. “The award is in recognition for the huge body of work which has gone into the development of ZedScan from a number of expert partners and the team at Zilico.” ENDS

Picture caption: Sameer Kothari (left) receives the Bionow Award from UL EduNeering’s Loretta Estevez Words: 297 For more information about Zilico please contact: Sameer Kothari, CEO, Zilico Ltd, tel: 0114 222 4580; mobile: 07736 403872; email: sameer.kothari@zilico.co.uk or visit www.zilico.co.uk Notes to Editors Zilico Ltd is a company developing the next generation of cancer diagnostics with a product line which will provide real-time diagnostics. Zilico has developed Electrical Impedance Spectroscopy, EIS, an objective scientifically-proven method to differentiate between normal and pre cancerous and cancerous cells (neoplasias), into a technology that can address the need for improved detection and diagnosis of neoplasia. The lead product is within the cervical cancer diagnostic pathway. Within this pathway two product applications are under development: the first for the referral market (patients) and the second for the screening market (women). ZedScan I, the first product within cervical cancer diagnostics, is positioned within the referral population, will reduce the number of biopsies taken and has the potential to

facilitate the wider use of ‘select & treat’ modality. Clinical data on over 1000 women has demonstrated superior performance over existing diagnostic procedures. Zilico’s patented technology, which has been discussed in learned peer-reviewed journals, exploits the different electrical resistivity of normal, pre-cancerous and cancerous cells. The Company has recently embarked on a proof-of-concept 50 patient trial for diagnosing oral lesions. The early development work was carried out at the Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield. Since incorporation in 2006, Zilico has focused on developing a research-based instrument into a device appropriate for commercial manufacture and routine use by medical practitioners. Both Zilico product applications consist of a handheld device and a base unit together with a Single-Use EIS Sensor for each test.